Aziyo Biologics Overview
Latest ROE for Aziyo Biologics: 329.02% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow329.02%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Aziyo Biologics's return on equity stands at 329.02%. That is above the Healthcare sector average of 21.28%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Aziyo Biologics sits higher the Healthcare benchmark (21.28%) with a ROE of 329.02%. That is roughly 1446.2% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 329.02% for Aziyo Biologics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Aziyo Biologics's ROE evolved across reporting periods, while the comparison chart places AZYO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Aziyo Biologics's reading of 329.02% (sector avg 21.28%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
